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Conspectus 
This Account highlights recent advances and discusses major challenges in the field of drug-
target recognition, binding, and unbinding studied using metadynamics-based approaches, with 
particular emphasis on their role in structure-based design. Computational chemistry has 
significantly contributed to drug design and optimization in an extremely broad range of areas, 
including prediction of target druggability and drug likeness, de novo design, fragment 
screening, ligand docking, estimation of binding affinity, and modulation of ADMET 
(absorption, distribution, metabolism, excretion, toxicity) properties. Computationally driven 
drug discovery must continuously adapt to keep pace with the evolving knowledge of the factors 
that modulate the pharmacological action of drugs. There is thus an urgent need for novel 
computational approaches that integrate the vast amount of complex information currently 
available for small (bio)organic compounds, biologically relevant targets and their complexes, 
while also accounting accurately for the thermodynamics and kinetics of drug-target association, 
the intrinsic dynamical behavior of biomolecular systems, and the complexity of protein-protein 
networks. Understanding the mechanism of drugs binding to and unbinding from biological 
targets is fundamental for optimizing lead compounds and designing novel biologically active 
ones. One major challenge is the accurate description of the conformational complexity prior to 
and upon formation of drug-target complexes. Recently, enhanced sampling methods, including 
metadynamics and related approaches, have been successfully applied to investigate complex 
mechanisms of drugs binding to flexible targets. Metadynamics is a family of enhanced sampling 
techniques aimed at enhancing the rare events and reconstructing the underlying free energy 
landscape as a function of a set of order parameters, usually referred to as collective variables. 
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Studies of drug binding mechanisms have predicted the most probable association and 
dissociation pathways and the related binding free energy profile. In addition, the availability of 
an efficient open-source implementation, running on cost-effective GPU (i.e. graphical processor 
unit) architectures, has considerably decreased the learning curve and the computational costs of 
the methods, and increased their adoption by the community. Here, we review the recent 
contributions of metadynamics and other enhanced sampling methods to the field of drug-target 
recognition and binding. We discuss how metadynamics has been used to search for transition 
states, to predict binding and unbinding paths, to treat conformation flexibility, and compute free 
energy profiles. We highlight the importance of such predictions in drug discovery. Major 
challenges in the field and possible solutions will finally be discussed. 
1. Introduction 
Approximately 12 years and over 1 billion dollars are required to develop one new medicine 
from the earliest stages of discovery to approval. Only a tiny percentage of the compounds 
entering the drug discovery pipeline reach the market. High-throughput screening (HTS) is one 
of the primary pharmaceutical methods for identifying lead compounds, but it has a high false 
positive rate. Candidates are not routinely translated into new drugs. This leads to the delay or 
failure of drug discovery projects.1 The reasons for this include unclear target biology, poor 
drug-like properties, low potency or selectivity, lack of efficacy, unexpected toxicity, etc. 
Failures in the later stages are extremely costly. It is therefore of paramount importance to 
identify early-on lead compounds that interact with the target in a biologically relevant 
mechanism without inducing adverse modes of action.  
In recent years, more dynamic models of molecular recognition have superseded Emil 
Fischer’s rigid lock-and-key binding paradigm. The two major paradigms are now the induced-
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fit and the conformational selection models.2 It is now increasingly clear that both mechanisms 
contribute to molecular recognition, which requires a dynamic description over timescales 
spanning several orders of magnitude to be fully understood. This presents a fundamental 
theoretical and computational challenge.3  
Molecular dynamics (MD) simulations have greatly contributed to understanding molecular 
recognition phenomena as a fully dynamical process. But they are limited by the timescales that 
can be routinely sampled. Very recently, with the introduction of special-purpose machines such 
as Anton,4 the porting of MD codes to GPUs,5 and the evolution of parallel codes,6,7 the 
timescales accessible by fully atomistic MD have increased enormously. Simulations lasting up 
to a few ms (corresponding to 1012 time-steps) are now possible. However, drug-like molecules 
with long residence times (more than an hour) are common, and their unbinding cannot be 
observed by conventional MD calculations even when specialized hardware is used. This well-
recognized limitation of MD is not limited to ligand binding and has led to the development of 
many innovative algorithms to enhance the sampling of the high-in-free-energy states and the 
rare events that allow the crossing of very high-free-energy barriers.8 
Enhanced sampling methods speed up conformational sampling by various means. Umbrella 
sampling,9 replica exchange,10 metadynamics,11 steered MD,12 accelerated MD,13 milestoning,14 
transition path sampling,15 and their many combinations and derivatives are among the most 
widely used methods to enhance conformational sampling. Of the enhanced sampling methods 
that fully explore the binding mechanism, metadynamics,11 especially in the well-tempered 
formulation,16 has emerged as a powerful approach for accelerating rare events and computing 
multidimensional free energy surfaces (FESs). Metadynamics is a family of methods that flatten 
the FES as a function of a set of collective variables (CVs), by introducing a bias that prevents 
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the system from being trapped in local free energy minima (Figure 1). It shares many similarities 
with other CV-based algorithms,17–22 and it has significantly evolved since its introduction. In 
contrast to other approaches, the reconstruction of the FES can be easily done in more than 2 
dimensions and does not require an additional step (such as WHAM23). It has been recently 
proved under general circumstances that well-tempered metadynamics provides an unbiased 
estimate of the free energy of the system projected onto predefined CVs, albeit the convergence 
time depends critically on how optimal are the CVs.24 By “optimal CVs”, one generally means a 
small set (2-4) of variables, function of the atomic positions (e.g. distance), whose combination 
provide a good description of the reaction coordinate and is able to clearly distinguish between 
different free energy minima, kinetic basins and binding pathways. 
An open source plug-in implementation of metadynamics (PLUMED)25 working with many 
widely-used MD codes, as well as native implementations for NAMD, Desmond and other codes 
are available. In drug discovery, it can provide the location of cryptic pockets, an estimate of the 
binding free energy, including conformational changes of the target, as well as quantitative 
information on the metastable minima and transition states, which can be used to optimize the 
underlying ligand binding and unbinding kinetics. 
In this Account, we review recent applications of metadynamics and compare it to other 
enhanced sampling approaches in drug-discovery-related endeavors, providing some perspective 
on the advantages, disadvantages, and practical applicability of these methodologies in academic 
and industrial settings. 
 
2. Protein-ligand binding and unbinding 
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MD simulations have contributed in major ways to our understanding of molecular recognition 
and consequently to drug design. HIV-integrase inhibitors are a classic example. MD simulations 
revealed a previously unknown “trench”, which was invisible to X-ray crystallography and 
traditional docking methods.26 This suggested a way of designing stronger inhibitors binding to 
both the catalytic site and the newly discovered trench. A few notable examples in the literature 
deal with the long time span required for a binding process to occur spontaneously, by running 
MD simulations lasting a few microseconds.27–29 However, the timescale problem still hampers 
an extensive application of fully atomistic MD in drug design. In the context of accelerated 
sampling methods, metadynamics-based approaches have been successfully applied to drug 
design, particularly when major conformational motions play a role prior to and upon a drug 
binding to a target.  
The first application of metadynamics to ligand-binding was carried out by Gervasio et al., 
who studied four different complexes.30 The correct geometry corresponded to the deepest free 
energy minimum in all the cases, demonstrating the ability of the method to predict the correct 
binding mode. In the case of the trypsin-benzamidine complex, the algorithm was extensively 
compared to 2D umbrella sampling and was found to provide the free energy reconstruction in 
less time. The experimental binding energy was correctly predicted. In the case of the 
CDK2/staurosporine complex, albeit the correct docking pose was predicted, the computed 
binding free energy was significantly overestimated (20 kcal/mol vs. 11 kcal/mol). This was due 
to: a fast filling time (a total of only 8 ns), an inaccurate ligand force-field, the lack of a 
correction for the standard volume of the unbound state and sub-optimal CVs. Nowadays, thanks 
to the significant increase in available computational resources and the introduction of the well-
tempered variant of metadynamics, the bias is added at a much slower rate and the FES is usually 
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filled in hundreds if not thousands of ns. The ligand force-field still remains a major concern. 
While there has been a significant progress in the accuracy of protein force-fields,31-32 generally-
available ligand force-fields lag behind, and despite recent progress,33 careful re-parameterization 
of ligands based on ab-initio calculations is strongly advised. As for the CVs, major progress has 
been achieved in the design of optimal coordinates. In Gervasio’s et al. paper30, the choice of 
geometry-based CVs (distance and angle) was guided by three requirements: i) a general 
applicability in molecular recognition, ii) the need to distinguish all the minima along the 
reaction coordinate, and iii) the need to keep the number of CVs low. The latter requirement is 
due to the fact that the time needed to “fill the minima” (see Figure 1) in principle increases 
exponentially with the number of the CVs.  
The need to choose a set of optimal CVs is the main drawback of metadynamics and other CV-
based methods. In a subsequent study, Masetti et al. systematically explored different 
combinations of CVs and faster approaches to converge the free energy estimation.34 A 
combination of docking, cluster analysis,35 and metadynamics limited to exploring the internal 
cavity up to the transition state (coarse-metadynamics) improved scoring in conventional 
structure-based endeavors. To date coarse-metadynamics together with optimal CVs is still one 
of the best ways to use metadynamics to rank different ligands binding to the same target. 
However, to compute the relative free energy of a set of similar compounds (having a similar 
binding pose), end-point methods, i.e. methods that compute the difference of free energy 
between the bound and the unbound state, such as thermodynamic integration (TI) are in most 
cases more efficient than methods that compute the free energy along a physical association 
pathway. 
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Another early application was Branduardi et al.’s study of the binding mechanism of the 
tetramethylammonium (TMA) ion by human acetylcholinesterase (AChE).36 The AChE 
peripheral anionic site (PAS), located at the entrance of the gorge, is solvent-exposed, therefore 
plain MD simulations are able to identify stable docking conformations.37 However, enhanced 
sampling approaches are needed to explore binding into the deep internal gorge.38 Metadynamics 
was run with two CVs, the distance between ligand and the binding pocket, along with a new CV 
describing the cation–π interaction, leading to a well-converged free energy reconstruction. 
Cation–π interactions were shown to play a fundamental role in both the initial recognition 
between TMA and the PAS, and the gorge binding mechanism. Notably, the cation–π CV must 
be included to obtain a converged FES.  
Beside protein-ligand systems, metadynamics has also been applied to study the association 
mechanism of molecules binding to DNA and RNA, e.g. the interaction of ligands with DNA G-
quadruplexes,39 and the unbinding of the anticancer drug distamycin from the DNA minor 
groove.40 
Other methods, such as steered MD, have also been successfully used to characterize binding 
poses and to drive the selection of biologically active compounds. Colizzi et al. have exploited 
docking and steered MD to discern between active and inactive antimalarial ligands.41 By 
modeling the force that is required to pulling inhibitors out of their binding pocket complex, it 
was possible to separate strong binders from weak ones. Strongly bound inhibitors gave profiles 
with higher peak forces than weakly bound inhibitors, which gave a flat profile (Figure 2). 
Compared to metadynamics, in steered MD the choice of the CV is less crucial, allowing a quick 
exploration of many unbinding events. However, it is less efficient in computing fully converged 
free energy profiles.  
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3. Reconstructing the free energy landscapes 
As discussed above, selecting a limited number of optimal CVs is a crucial step in 
metadynamics simulations to obtain a converged free energy landscape. The most commonly 
used CVs in drug-binding simulations are geometry-based and involve a combination of 
distances, contacts, angles, and dihedrals. In complex cases, several attempts might be needed to 
find a proper combination of variables (sub-optimal set of variables are easily recognized as the 
reconstructed FES shows hysteresis as a function of time). The selection of effective CVs in 
ligand-(un)binding is further complicated by the need to fully explore (fill) the large 
conformational spaces available to the solvated ligand in the bulk, once unbound from its target.  
Metadynamics is not efficient in exploring relatively flat, diffusive energy landscapes and its 
use to explore unbound and weakly-bound states is not recommended. In such cases, other 
methods such as swarms of free MD trajectories and Markov-state Models28 or some 
metadynamics variants such as Recoinnascence metadynamics or bias-exchange are more 
effective. When the binding area is known, this issue can be solved by the use of restraints on the 
explored area or optimal CVs such as the Path Collective Variables (PCVs).42  
In analogy to similar strategies used with umbrella-sampling,43 various restraining potentials 
have been used. An interesting choice is to use a reverse funnel-shaped potential that limits the 
space available to the ligand once it has undocked.44 Funnel metadynamics was used to revisit 
some of the systems previously studied with geometrical CVs or PCVs, including the trypsin-
benzamidine complex and the binding of the drug SC-558 to cyclooxygenase 2 (COX-2, see 
below). Thanks to the restraining potential, the unbound state can be thoroughly sampled leading 
to a faster convergence of the energy landscape.   
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A perhaps more elegant solution is the use of PCVs that describe the position of the system in 
the configuration space relative to an optimal exit path, in terms of progression along the path 
and distance from the path itself. PCVs are able to describe complex association pathways 
including target conformational changes and to restrain the sampling of the unbound state, 
improving convergence considerably. In the last few years, the PCV approach has been 
successfully used to study complex conformational changes and drug-target binding.45,46 Fidelak 
et al.47 used PCVs to study the binding of a congeneric series of ligands to CDK2. Identifying the 
correct order of activity of the compounds was non-trivial, due to the lack of interaction between 
the protein and the aryl-pyrimidine substituents differentiating the homologous inhibitors. Using 
well-tempered metadynamics and PCV, the authors converged a full association free energy 
profile in remarkable agreement with the experimental binding energies. They also fully 
characterized the association mechanism. In a subsequent work, Saladino et al.48 studied a well-
known series of p38 inhibitors, frequently used to assess the performances of scoring algorithms, 
whose activity cannot be easily guessed. The authors moved a step further towards making 
metadynamics suitable for a pharmaceutical workflow and used a semi-automatic setup. With a 
similar intent, Mason and coworkers49 at Heptares Therapeutics designed the MetaScore routine, 
a fast metadynamics-based protocol, used to predict the effect of different mutations on the 
binding of antagonists to the adenosine A2A receptor. The MetaScore scoring function is based on 
a two-step semi-automatic protocol that uses several adiabatic biased MD simulations to obtain 
an initial association path and construct PCVs, followed by short well-tempered metadynamics 
runs to calculate the full binding free energy profile. Using this approach, the authors predicted 
the correct binding energy changes resulting from active site mutations. PCV were also used by 
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Provasi et al.50 to access the free energy of binding of several ligands to another G-protein-
coupled receptor, the β2-adrenergic receptor. 
When the binding is accompanied by large-scale conformational changes, the choice of CVs 
can be daunting. In such cases, Parallel Tempering Metadynamics (PT-MetaD)51, an approach 
that couples metadynamics with a replica exchange algorithms, can enhance the sampling of 
hidden (slow) degrees of freedom and greatly improve convergence. It has been used to compute 
the FES associated with the inactive-to-active conformational changes of the cancer target 
epidermal growth factor receptor.46 PT-metaD, albeit being a very expensive approach, is the 
method of choice when large-scale conformational changes are involved and a converged FES is 
required. Finally, the number of CVs is not an issue in Bias Exchange Metadynamics (BEMD)52 
and Reconnaissance Metadynamics.53 The latter uses a self-learning algorithm that clusters the 
visited conformations on-the-fly and bias along a one-dimensional clustering-based CV. These 
approaches have been effectively used to explore very complex molecular recognition events and 
are very beneficial when little information is known about the association mechanism and the 
location of the binding cavity. Both methods, however, require extra efforts to reconstruct the 
free energy landscapes, and thus are best used as a means to explore different binding 
mechanisms. 
 
4. Pharmaceutical applications 
Metadynamics was recently used to understand the differences in the binding mechanisms of a 
non-steroidal anti-inflammatory ligand (SC-558) to COX-1 and COX-2 isoforms.54 Selective 
inhibition of COX isoforms has been actively sought, leading to new generations of widely used 
COX-2 selective drugs. Recently, significant effort has been made to understand the selectivity 
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and the differences in the binding mechanism of inhibitors to COX-1 and COX-2. In this study, 
metadynamics and the PCV method42 were used to describe the (un)binding of a ligand and the 
associated conformational change of three α-helices that form a narrow gate through which the 
ligand exits from the protein. In the case of the COX-2 isoform, two separate and almost equally 
favorable minima in the FES are found (Figure 3), while only one deep minimum was found in 
COX-1. The existence of two binding modes in COX-2 only explain both the selectivity of the 
ligand and, interestingly, the increased residence time of the ligand in COX-2 relative to COX-1.  
A similar approach was used to study the aspartate uptake and internal release mechanism 
through a membrane protein, namely the amino acid transporter from Pyrococcus horikoshii.55 
The transport of the substrate is assisted by the cotransport of Na+ ions and is mediated by the 
concerted motion of the transmembrane domain and the two hairpins (HP1 and HP2) that 
regulate access to either side of the membrane. In addition, it is known that this transporter may 
assume at least four different conformational states, which further challenges the study of the 
substrate translocation across the channel. Grazioso et al. used PCV to enhance the highly 
cooperative transition upon substrate binding and transport across the membrane.55 The authors 
thus described the complete opening mechanism involving a large-scale motion of HP2, which 
allowed substrate uptake, with a similar role played by HP1 in the inward release mechanism 
(Figure 4).  
As a final case study, PT-metaD with PCVs and BEMD have been used to study the mode of 
action of a novel inhibitor of the fibroblast growth factor receptor (FGFR).56 FGFRs are tyrosine 
kinase receptors whose signaling pathway is involved in cell growth, proliferation, and survival. 
Due to their key role in angiogenesis, FGFR deregulation can lead to the development of 
malignancies, so this family of receptors is a well-studied target for cancer treatment. The first 
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extracellular FGFR inhibitor, SSR128129E (hereafter referred to as SSR), was discovered by the 
same authors through a high-throughput screening campaign.  However, several experimental 
techniques, ranging from NMR to crystallography, failed to identify the binding site of SSR, due 
to the inherent flexibility of the extracellular domain of FGFR, comprising three 
immunoglobulin-like domains. Using BEMD, the authors observed the elongation of a small α-
helix in the D3 domain in the presence of the drug, leading to the opening of a pocket not present 
in the apo structure of FGFR. Metadynamics simulations with PCV correctly predicted the 
dissociation constant of the compound and of several lower potency analogues, validating the in-
silico-derived mode of action. As a further proof, the authors used the observed binding mode as 
a template for rationally designing new inhibitors, identifying 16 new compounds with varying 
degrees of activity. Once again, the computationally predicted free energy was in remarkable 
agreement with experimental results. 
 
5. Binding and unbinding kinetics estimation 
Obtaining reliable estimates of the kinetics constants associated with ligand binding is an 
ambitious goal of modern computational drug discovery, with significant potential benefits in the 
lead discovery and the lead optimization steps of the drug discovery process.57 The possibility of 
reconstructing and estimating the binding free energy along physical association pathways 
provides quantitative information on the metastable minima and transition states. These can then 
be used to optimize the underlying ligand binding kinetics to achieve therapeutically safe and 
differentiated responses. Researchers increasingly recognize the importance of ligand target 
residence time in fine-tuning in vivo efficacy and toxicology.58 Knowledge of the metastable 
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states and the residues involved in a ligand’s access to the binding cavity could lead to the design 
of novel drugs that are more potent and selective for therapeutically relevant targets. 
Metadynamics in the bias-exchange variant was used by Pietrucci et al. to investigate the key 
events in the binding of the p2-NC peptide to the Human Immunodeficiency Virus type-1 
Protease (HIV1-1 PR).59 The free energy was computed as a function of seven CVs, in order to 
characterize the physical interactions that might play a role in stabilizing the complex and the 
transition states. From the BE-META trajectories, a thermodynamic and kinetic model of the 
binding process was constructed based on the weighted-histogram approach (Figure 5). 
Remarkably, mutation of residues along the access region identified by BE caused resistance to 
some FDA-approved peptidomimetic drugs, providing an experimental validation. Individual 
water molecules at the interface between ligand and enzyme played a pivotal role throughout the 
binding process and a CV describing “interfacial water” was needed to discriminate different 
intermediate states. 
In absence of large barriers to binding/unbinding, Markov state models (MSM)60 might be 
more efficient than metadynamics-based algorithms in reconstructing the binding kinetics. A 
collection of 495 100-ns-long trajectories was used to reconstruct the full binding kinetics of the 
trypsin/benzamidine complex, revealing the existence of long-lived binding intermediates. 
Recently, Tiwary et al.61 adapted to metadynamics the concept of “acceleration factor” 
introduced by Grubmüller17 for Conformational Flooding. Provided that no bias is deposited in 
the transition state region, this approach can predict the rate of the transition, with minimal 
additional computational cost. Albeit the authors applied their approach to a toy model, 
preliminary data indicates that it can be applied to predict the binding kinetics in simple (2-state) 
systems. A more general (and more computationally expensive) approach was developed by 
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Juraszek and coworkers.62 By combining PT-metaD-derived free energies with a transition path 
sampling (TPS) approach they devised a robust method that can be applied to complex ligand-
binding events with multiple intermediate states and diffusive barriers. Indeed, the Transition 
State-Partial Path Transition Interface Sampling was explicitly devised to overcome the 
difficulties of available methods in predicting the kinetics rates of drug binding phenomena. 
Introducing a new recursive expression for the transmission coefficient, the authors designed a 
robust  approach with very general applicability and high accuracy.  
 
6. Perspectives 
In Table 1 and Figure 6, we summarize the suggested metadynamics-based approach to use in 
drug discovery. In particular we address the cases of cryptic binding sites, scoring different 
ligands binding to the same target, full free energy reconstruction with or without large 
conformational changes and binding kinetics. As we have detailed in the preceding sections, 
metadynamics-based approaches are not always the most effective choice. In Figure 7, we report 
on the major strengths and weaknesses of these methods. One of major drawbacks of 
metadynamics is still related to the choice of CVs, which can compromise a proper 
reconstruction of the FES associated to the process under investigation. In this scenario, some 
recent and on-going developments, particularly suited to drug discovery, are the use of non-
linear dimensionality reduction techniques to automatically find the optimal CVs, new CVs to 
find and score cryptic binding sites and, going beyond the current methods, a new variational 
approach to construct an optimal bias potential and reconstruct the FES.63 All these evolutions 
will contribute to a further expansion of metadynamics approaches to drug discovery, widening 
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the plethora of computational tools utilized to estimate binding and unbinding free energy and 
kinetics, and eventually accelerating the discovery of novel bioactive compounds. 
 
Figure Legends 
Figure 1. Pictorial representation of the way the metadynamics algorithm fills the free energy 
landscapes. 
Figure 2. The force applied to the ligand by the spring is calculated as a function of time, 
generating a force profile that reflects the strength of protein–ligand binding as reported in 
Colizzi et al.41 
Figure 3. Free energy surfaces associated with the binding of the SC558 inhibitor to COX-1 and 
COX-2 as a function of the distance between the ligand and the cavity and the relative 
orientation of SC558.  
Figure 4. Schematic representation of the free energy landscape of substrate uptake and release 
by the glutamate transporter. Adapted from Grazioso et al.55 
Figure 5. Kinetic model of the substrate binding to HIV-1 Protease. Adapted from Pietrucci et 
al.59 
Figure 6.  Schematic representation of the use of metadynamics in drug design, from scoring and 
binding pose prediction to thermodynamics and kinetics profiles. 
Figure 7. SWOT (Strengths, Weakness, Opportunities and Threats) analysis for metadynamics. 
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Table 1. Summary of the suggested approaches for different drug discovery applications. 
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